J Vet Sci.  2012 Jun;13(2):199-201. 10.4142/jvs.2012.13.2.199.

Evaluation of modified vaccinia virus Ankara expressing VP2 protein of infectious bursal disease virus as an immunogen in chickens

• Zanetti FA
• Zajac MP
• Taboga OA
• Calamante

• KMID: 1376195
• DOI: http://doi.org/10.4142/jvs.2012.13.2.199

Abstract

A recombinant modified vaccinia Ankara (MVA) virus expressing mature viral protein 2 (VP2) of the infectious bursal disease virus (IBDV) was constructed to develop MVA-based vaccines for poultry. We demonstrated that this recombinant virus was able to induce a specific immune response by observing the production of anti-IBDV-seroneutralizing antibodies in specific pathogen-free chickens. Besides, as the epitopes of VP2 responsible to induce IBDV-neutralizing antibodies are discontinuous, our results suggest that VP2 protein expressed from MVA-VP2 maintained the correct conformational structure. To our knowledge, this is the first report on the usefulness of MVA-based vectors for developing recombinant vaccines for poultry.

Keyword

chicken immunity; IBDV; MVA; VP2 protein

MeSH Terms

Animals
Antibodies, Viral
Birnaviridae Infections/prevention & control/*veterinary
Cells, Cultured
Chick Embryo
Chickens
Fibroblasts/metabolism
Infectious bursal disease virus/*immunology
Poultry Diseases/*prevention & control/virology
Specific Pathogen-Free Organisms
Vaccinia virus/*genetics/immunology/metabolism
Viral Structural Proteins/genetics/*immunology/metabolism
Viral Vaccines/*immunology

Figure

• 

  Fig. 1 Expression of mature viral mature protein 2 (VP2) from modified vaccinia Ankara-VP2 recombinant virus. (A) The cytoplasmic expression of the VP2 protein was evaluated by an immunofluorescence assay in DF1 cells infected with MVA-VP2. As a control, uninfected (B) or MVA-infected DF1 cells (C) were included. Scale bars = 25 µm.

Reference

1. Becht H. Infectious bursal disease virus. Curr Top Microbiol Immunol. 1980. 90:107–121.

2. Breathnach CC, Clark HJ, Clark RC, Olsen CW, Townsend HG, Lunn DP. Immunization with recombinant modified vaccinia Ankara (rMVA) constructs encoding the HA or NP gene protects ponies from equine influenza virus challenge. Vaccine. 2006. 24:1180–1190.

3. Ferrer MF, Zanetti FA, Calamante G. Design and construction of transfer vectors in order to obtain recombinant modified vaccinia virus Ankara (MVA). Rev Argent Microbiol. 2007. 39:138–142.

4. Francois A, Chevalier C, Delmas B, Eterradossi N, Toquin D, Rivallan G, Langlois P. Avian adenovirus CELO recombinants expressing VP2 of infectious bursal disease virus induce protection against bursal disease in chickens. Vaccine. 2004. 22:2351–2360.

5. Jackwood DJ, Saif YM, Moorhead PD, Dearth RN. Infectious bursal disease virus and Alcaligenes faecalis infections in turkeys. Avian Dis. 1982. 26:365–374.

6. Kim IJ, You SK, Kim H, Yeh HY, Sharma JM. Characteristics of bursal T lymphocytes induced by infectious bursal disease virus. J Virol. 2000. 74:8884–8892.

7. Lai SY, Lee MS, Chen HC, Shen PC, Jinn TR, Kao SS, Wang MY. Production and purification of immunogenic virus-like particles formed by the chimeric infectious bursal disease virus structural protein, rVP2H, in insect larvae. Process Biochem. 2004. 39:571–577.

8. Moss B, Carroll MW, Wyatt LS, Bennink JR, Hirsch VM, Goldstein S, Elkins WR, Fuerst TR, Lifson JD, Piatak M, Restifo NP, Overwijk W, Chamberlain R, Rosenberg SA, Sutter G. Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates. Adv Exp Med Biol. 1996. 397:7–13.

9. Porter DW, Thompson FM, Berthoud TK, Hutchings CL, Andrews L, Biswas S, Poulton I, Prieur E, Correa S, Rowland R, Lang T, Williams J, Gilbert SC, Sinden RE, Todryk S, Hill AV. A human Phase I/IIa malaria challenge trial of a polyprotein malaria vaccine. Vaccine. 2011. 29:7514–7522.

10. Shaw I, Davison TF. Protection from IBDV-induced bursal damage by a recombinant fowlpox vaccine, fpIBD1, is dependent on the titre of challenge virus and chicken genotype. Vaccine. 2000. 18:3230–3241.

11. Vakharia VN, He J, Ahamed B, Snyder DB. Molecular basis of antigenic variation in infectious bursal disease virus. Virus Res. 1994. 31:265–273.